<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2 xmlns:ns2="local" rowCount="169"><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10223"></Trial><Drug id="84867">Vaxem HIB</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>216</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Reference>2006-003476-35; NCT00488683; V59P16</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11389"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1439</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1439</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Reference>104020; 2004-005123-18; MeMuRu-OKA 043; NCT00126997</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11525"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>752</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><EnrollmentCount>752</EnrollmentCount><Interventions>Varivax</Interventions><Reference>EudraCT#2004_002586_21; NCT00432523; V205-011; X04-MMRr-301</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124248"></Trial><Drug id="56585">Vaxelis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Sponsor>Health Protection Agency</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="132011"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers>Immunoglobulin G; Serum bactericidal antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Menitorix; Prevnar 13; Priorix</Interventions><Reference>12/LO/1875; 2012-005110-18; HPA Protocol No: 12/05; ISRCTN84763401; P13Boost; UKCRN 13975</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="161697"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1560</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1560</EnrollmentCount><Interventions>MMR vaccine, Bio-Manguinhos/Fiocruz; Priorix</Interventions><Reference>ASCLIN/002/2013; NCT01991899</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="203343"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>1736</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="203343"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>1736</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233238"></Trial><Drug id="17674">Infanrix Quinta</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60653"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>822</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Comvax; Tripedia; Varivax</Controls><EnrollmentCount>1913</EnrollmentCount><Interventions>Comvax; ProQuad; Tripedia</Interventions><Reference>2009_666; NCT00984295; V221-013</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60684"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1551</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR-II; PUVV</Controls><EnrollmentCount>1551</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2009_667; NCT00986232; V221-011</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ProQuad Dose Selection Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60684"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1551</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR-II; PUVV</Controls><EnrollmentCount>1551</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2009_667; NCT00986232; V221-011</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88475"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4011</Patients><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91153"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4538</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94105"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>5016</Patients><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9949"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1128</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><EnrollmentCount>1128</EnrollmentCount><Interventions>Menactra; Menactra; PCV; ROR Vax</Interventions><Reference>MTA44; NCT00384397</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Non-blind, randomized trial to evaluate the safety and immunogenicity of JVC-001 intended for Japanese healthy children</ProtocolTitle><Sponsor>Japan Vaccine Co Ltd</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="244020"></Trial><Drug id="99518">JVC-001</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>100</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount></EnrollmentCount><Interventions>JVC-001</Interventions><Reference>JapicCTI-153031</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Sponsor>Themis Bioscience GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268409"></Trial><Drug id="75100">MV-CHIK</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>263</Patients><Biomarkers>Anti-Chikungunya virus antibodies; Anti-Measles antibodies; Mononuclear leukocytes; T-Lymphocytes</Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><EnrollmentCount>263</EnrollmentCount><Interventions>MV-CHIK; MV-CHIK; Priorix</Interventions><Reference>2015-004037-26; MV-CHIK-202; NCT02861586</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="102759"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>458</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>446</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix</Interventions><Reference>105908; EudraCT: 2005-006065-14; MeMuRu-OKA 046; NCT00353288</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10599"></Trial><Drug id="17821">Infanrix HeXa</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>955</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix hexa; ProQuad</Controls><EnrollmentCount>955</EnrollmentCount><Interventions>Infanrix hexa; ProQuad</Interventions><Reference>2006-004129-27; NCT00432042; V221-035; X06-MMRV-302</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase III Study Of Prophylactic Antibiotics in Measles</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11380"></Trial><Drug id="44363">trimethoprim + sulphamethoxazole</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>218</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>218</EnrollmentCount><Interventions>trimethoprim + sulfamethoxazole</Interventions><Reference>NCT00168532; ProfAnt-BHP-1996</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11511"></Trial><Drug id="3263">Vaqta</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1800</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1800</EnrollmentCount><Interventions>ProQuad; Vaqta</Interventions><Reference>2006_023; NCT00326183; V251-066</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11515"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>M-M-R II; ProQuad; Varivax</Interventions><Reference>04-073; NCT00258726</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11526"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1783</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124248"></Trial><Drug id="55366">Nimenrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="172270"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>869</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><EnrollmentCount>996</EnrollmentCount><Interventions>Priorix</Interventions><Reference>115231; 2011-003672-36; 209762; MMR-159; NCT02058563</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality. Burkina Faso</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="200688"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>4050</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>4050</EnrollmentCount><Interventions>measles vaccine (inhaled aerosol), WHO</Interventions><Reference>NCT01668745; OPTIMUNISE_NOUNA_EARLY MV</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="203343"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>1736</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Measles, Mumps, and Rubella (MMR) Immunity in College Students</ProtocolTitle><Sponsor>Emory University</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59758"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>74</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>74</EnrollmentCount><Interventions>ROR Vax</Interventions><Reference>IRB00007373; NCT00962819</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77052"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3340</Patients><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77052"></Trial><Drug id="30214">diphtheria/tetanus/pertussis vaccine, sanofi pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3340</Patients><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79465"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1220</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88475"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4011</Patients><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88475"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4011</Patients><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91153"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4538</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94105"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>5016</Patients><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9859"></Trial><Drug id="55366">Nimenrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1000</Patients><Biomarkers>Meningococcal rSBA</Biomarkers><Condition>Measles virus infection</Condition><Controls>Meningitec; Priorix-Tetra</Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>Nimenrix; Nimenrix + Priorix-Tetra; Priorix-Tetra; Priorix-Tetra + Meningitec</Interventions><Reference>109670; NCT00474266</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>HVT</ProtocolAcronym><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Sponsor>McMaster University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265194"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Adacel; Priorix</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Diphtherinum; Morbilinum; Ourlianum; Pertussinum; Tetanotxicum</Interventions><Reference>HVT; HVT-2016; NCT02825368</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="340960"></Trial><Drug id="22877">RotaTeq</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2475</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Reference>MET42; NCT03537508</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="340960"></Trial><Drug id="102979">quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2475</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Reference>MET42; NCT03537508</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10223"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>216</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Reference>2006-003476-35; NCT00488683; V59P16</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11387"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>559</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>559</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Reference>103388; MMRV-042; NCT00127010</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11418"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>5803</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><EnrollmentCount>5735</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix; Varilrix + Priorix</Interventions><Reference>100388; 100388 (OKAH-179); 103494; 103494 (EXT FU Y1); 103494 (OKAH-180 EXT 179 Y1); 104105; 104105 (EXT FU Y2); 104105 (OKAH-181 EXT 179 Y2); 104106; 104106 (EXT FU Y4-Y6-Y8-Y10); 111433; 180 Y1; 181 Y2; 182 Y4-Y6-Y8-Y10; 2004-002676-41; NCT00226499; OKAH-179 and EXT</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Assess GSK Biologicals' MMR Vaccine (Priorix) When Given to Healthy Children at the Age of 12 to 18 Months in Singapore</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11425"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Priorix</Interventions><Reference>209762/147; NCT00388440</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11515"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>M-M-R II; ProQuad; Varivax</Interventions><Reference>04-073; NCT00258726</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity/Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA): Using Two Different Administration Routes</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11963"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>330</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>330</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Reference>106670; EudraCT: 2005-005944-22; NCT00351923</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124248"></Trial><Drug id="22877">RotaTeq</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="187831"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>Priorix-Tetra; Varilrix + Priorix</Interventions><Reference>105909; 2005-005825-75; NCT00352898</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Additional Measles Vaccine to Reduce Child Mortality</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="198691"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>8309</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>3750</EnrollmentCount><Interventions>measles vaccine (inhaled aerosol), WHO</Interventions><Reference>NCT01644721; OPTIMUNISE_BHP_EARLY MV</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85664"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9949"></Trial><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1128</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><EnrollmentCount>1128</EnrollmentCount><Interventions>Menactra; Menactra; PCV; ROR Vax</Interventions><Reference>MTA44; NCT00384397</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9965"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1378</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>HepA; MMRV; Prevnar</Controls><EnrollmentCount>1378</EnrollmentCount><Interventions>HepA; Menactra; Menactra; Prevnar; ProQuad</Interventions><Reference>MTA48; NCT00483574</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Sponsor>Path Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="269874"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>628</Patients><Biomarkers>Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>628</EnrollmentCount><Interventions>Priorix; SA-14-14-2</Interventions><Reference>JEV06 (862058-1); NCT02880865</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>HVT</ProtocolAcronym><ProtocolTitle>Homeopathic Vaccine Trial</ProtocolTitle><Sponsor>McMaster University</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="265194"></Trial><Drug id="47199">Adacel</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Adacel; Priorix</Controls><EnrollmentCount>150</EnrollmentCount><Interventions>Diphtherinum; Morbilinum; Ourlianum; Pertussinum; Tetanotxicum</Interventions><Reference>HVT; HVT-2016; NCT02825368</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="340960"></Trial><Drug id="59852">Pentaxim</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2475</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Reference>MET42; NCT03537508</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="102759"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>458</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>446</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix</Interventions><Reference>105908; EudraCT: 2005-006065-14; MeMuRu-OKA 046; NCT00353288</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of Proquad and Infanrix Hexa When Administered Concomitantly</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10599"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>955</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix hexa; ProQuad</Controls><EnrollmentCount>955</EnrollmentCount><Interventions>Infanrix hexa; ProQuad</Interventions><Reference>2006-004129-27; NCT00432042; V221-035; X06-MMRV-302</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11418"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>5803</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><EnrollmentCount>5735</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix; Varilrix + Priorix</Interventions><Reference>100388; 100388 (OKAH-179); 103494; 103494 (EXT FU Y1); 103494 (OKAH-180 EXT 179 Y1); 104105; 104105 (EXT FU Y2); 104105 (OKAH-181 EXT 179 Y2); 104106; 104106 (EXT FU Y4-Y6-Y8-Y10); 111433; 180 Y1; 181 Y2; 182 Y4-Y6-Y8-Y10; 2004-002676-41; NCT00226499; OKAH-179 and EXT</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Hepatitis A Vaccine Given at the Same Time of Measles, Mumps, Rubella Combined Vaccine</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11423"></Trial><Drug id="14438">Avaxim</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>470</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>470</EnrollmentCount><Interventions>Avaxim; Trimovax</Interventions><Reference>2015-005192-24; HAF65; NCT00313950</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of ProQuad rHA in Infants</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11426"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3388</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>3388</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2007-002438-12; MRV01C; NCT00560755; V221-037</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11526"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1783</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11526"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1783</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>ProQuad Intramuscular versus Subcutaneous</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11634"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>405</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>405</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2006-001986-40; F05-MMRV-304; NCT00402831; V221-036</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunological Effect of Early Extra MMR Immunization in Infants Between 6 and 12 Months of Age in an Outbreak Setting</ProtocolTitle><Sponsor>National Institute for Public Health and the Environment</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="156178"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>100</Patients><Biomarkers>IgG</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>100</EnrollmentCount><Interventions>MMR; NeisVac-C</Interventions><Reference>2013-003078-28; IIV-273</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of Immunogenicity, Reactogenicity and Safety of the Combined Measles, Mumps and Rubella Vaccine Produced by Bio-Manguinhos/Fiocruz in Children 12 to 15 Months of Age, Followed by Tetraviral Vaccine in Children 15 to 18 Months</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="161697"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1560</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1560</EnrollmentCount><Interventions>MMR vaccine, Bio-Manguinhos/Fiocruz; Priorix</Interventions><Reference>ASCLIN/002/2013; NCT01991899</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GSK Biologicals Combined Measles-Mumps-Rubella Vaccine in Volunteers, 7 Years of Age and Older</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="172270"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>869</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><EnrollmentCount>996</EnrollmentCount><Interventions>Priorix</Interventions><Reference>115231; 2011-003672-36; 209762; MMR-159; NCT02058563</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Sponsor>Crucell Switzerland AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="17279"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>467</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>ROR Vax</Controls><EnrollmentCount>467</EnrollmentCount><Interventions>second-generation MMR vaccine, Berna</Interventions><Reference>PMID: 16371870</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase IV, Open, Multicentric, Post-marketing Surveillance Study to Monitor the Safety and Reactogenicity of GlaxoSmithKline Biologicals’ Live Attenuated Measles-Mumps-Rubella vaccine (Priorix) in Korean Subjects Administered According to the Prescribing Information</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="172850"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>732</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>600</EnrollmentCount><Interventions>Priorix</Interventions><Reference>209762-145 (MeMuRu-145)</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="184151"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1412</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>ProQuad</Controls><EnrollmentCount>1412</EnrollmentCount><Interventions>M-M-R II</Interventions><Reference>2017-001443-13; NCT01536405; P20930; V221-027</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="187831"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>Priorix-Tetra; Varilrix + Priorix</Interventions><Reference>105909; 2005-005825-75; NCT00352898</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="203343"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>1736</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals Measles, Mumps and Rubella (MMR) Vaccine (209762) Compared to Merck and Co, Inc's MMR Vaccine in Healthy Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="203343"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>1736</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar 13; Varivax</Controls><EnrollmentCount>1743</EnrollmentCount><Interventions>Havrix; M-M-R II; Prevnar 13; Priorix; Varivax</Interventions><Reference>115650; 2011-006161-18; MMR-162; NCT02184572</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233238"></Trial><Drug id="42065">Bexsero</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="44865"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR II; Varivax</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2009_538; NCT00839917; V221-023</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60050"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>450</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>450</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Priorix-Tetra</Interventions><Reference>109995; 2011-005882-19; MMRV-053 PRI; NCT00969436</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77052"></Trial><Drug id="44408">polio vaccine, Sanofi Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3340</Patients><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79465"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1220</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79465"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1220</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83852"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>716</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>716</EnrollmentCount><Interventions>Meningitec; Priorix-Tetra</Interventions><Reference>115555; 115555MMRV-063; 2011-001608-37; MMRV-063; NCT01506193</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85664"></Trial><Drug id="56585">Vaxelis</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85664"></Trial><Drug id="3612">meningococcal C/CRM-197 conjugate vaccine, Chiron</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94105"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>5016</Patients><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9967"></Trial><Drug id="7167">Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1664</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><EnrollmentCount>1664</EnrollmentCount><Interventions>Menactra</Interventions><Reference>MTA37; NCT00422292</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9967"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1664</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><EnrollmentCount>1664</EnrollmentCount><Interventions>Menactra</Interventions><Reference>MTA37; NCT00422292</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Japanese Encephalitis Vaccine When Given With Measles-Mumps-Rubella Vaccine</ProtocolTitle><Sponsor>Path Inc</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="269874"></Trial><Drug id="60890">SA-14-14-2</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>628</Patients><Biomarkers>Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>628</EnrollmentCount><Interventions>Priorix; SA-14-14-2</Interventions><Reference>JEV06 (862058-1); NCT02880865</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Vyriad</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="273428"></Trial><Drug id="101326">MV-NIS (lung cancer), Vyriad</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>4</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>4</EnrollmentCount><Interventions>MV-NIS (lung cancer), Vyriad; atezolizumab</Interventions><Reference>NCT02919449; VYR-MV1-101</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Post Licensure Clinical Trial to Assess the Safety and Tolerability of BE’s Measles-rubella Vaccine in 9 to 12 Months Old Healthy Infants in a Single-Dose</ProtocolTitle><Sponsor>Biological E Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="378426"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1000</Patients><Biomarkers>Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>measles/rubella vaccine, Biological E</Interventions><Reference>BECT048/MRV-PIV/CTP-02; CTRI/2019/04/018683</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10223"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>216</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Reference>2006-003476-35; NCT00488683; V59P16</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MeMuRu-OKA 046</ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-Mumps-Rubella-Varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="102759"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>458</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>446</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix</Interventions><Reference>105908; EudraCT: 2005-006065-14; MeMuRu-OKA 046; NCT00353288</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Phase II, Comparative Study of Seroconversion of Single-Dose and Two-Dose Measles Vaccination in HIV-Infected and HIV-Uninfected Children: A Multicenter Trial of the Pediatric AIDS Clinical Trials Group</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11384"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>110</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>270</EnrollmentCount><Interventions>Attenuvax; MMR vaccine, Merck &amp; Co; MMR vaccine, Merck &amp; Co</Interventions><Reference>11202; ACTG 225; NCT00000815</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11388"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>970</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>944</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Reference>104389; EudraCT: 2004-005263-19; NCT00127023</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11388"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>970</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>944</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Reference>104389; EudraCT: 2004-005263-19; NCT00127023</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluate Vaccine Against Chickenpox and a Combined Vaccine Against 4 Viral Childhood Diseases: Measles, Mumps, Rubella and Chickenpox</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11418"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3B">Phase 3b Clinical</DevStatus><Patients>5803</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><EnrollmentCount>5735</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Varilrix; Varilrix + Priorix</Interventions><Reference>100388; 100388 (OKAH-179); 103494; 103494 (EXT FU Y1); 103494 (OKAH-180 EXT 179 Y1); 104105; 104105 (EXT FU Y2); 104105 (OKAH-181 EXT 179 Y2); 104106; 104106 (EXT FU Y4-Y6-Y8-Y10); 111433; 180 Y1; 181 Y2; 182 Y4-Y6-Y8-Y10; 2004-002676-41; NCT00226499; OKAH-179 and EXT</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immune Responses to Two Dose Varivax +/- MMR-II</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="11515"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>105</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>105</EnrollmentCount><Interventions>M-M-R II; ProQuad; Varivax</Interventions><Reference>04-073; NCT00258726</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>MMRV-054 PRI</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of GlaxoSmithKline Biologicals' MMRV Vaccine versus ProQuad in Children 12 to 14 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11526"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1783</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; Prevnar; Pro-Quad</Controls><EnrollmentCount>1851</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix-Tetra</Interventions><Reference>110058; 110058_1; 2017-000454-18; BB-IND 13510; MMRV-054 PRI; NCT00578175</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124248"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124248"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Long-term Follow-up of Measles Antibodies</ProtocolTitle><Sponsor>Bandim Health Project</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="14946"></Trial><Drug id="56118">measles vaccine (inhaled aerosol), WHO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>1960</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1960</EnrollmentCount><Interventions>Schwarz measles vaccine; measles vaccine (inhaled aerosol), WHO</Interventions><Reference>LTAB-2288/2292-Twodose1; Lægevidenskabens Fremme-2292; NCT00168571; NOVO-2288</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Study To Compare The Immune Response And Safety Of Measles Vaccine Manufactured By Cadila Healthcare Ltd, With Measles Vaccine Manufactured By Serum Institute Of India Ltd, In Children 9 to 12 Months Of Age</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="229988"></Trial><Drug id="97346">measles vaccine, Cadila Healthcare</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>327</Patients><Biomarkers>Anti-Measles antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>measles vaccine (live, freeze-dried), Serum Institute of India Limited</Controls><EnrollmentCount>327</EnrollmentCount><Interventions>measles vaccine, Cadila healthcare</Interventions><Reference>14-05; CTRI/2015/05/005739</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233238"></Trial><Drug id="12813">Rotarix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>BIOMR</ProtocolAcronym><ProtocolTitle>Study to Evaluate the Immunogenicity, Reatogenicity and Safety of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="298150"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>432</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Bio-Manguinhos/Fiocruz</Controls><EnrollmentCount>432</EnrollmentCount><Interventions>double viral vaccine (measles and rubella), Bio-Manguinhos/Fiocruz</Interventions><Reference>ASCLIN 002/2017; BIOMR; NCT03148990</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="44865"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR II; Varivax</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2009_538; NCT00839917; V221-023</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of PriorixTetra When Co-administered With Conjugated MenC Vaccine in Healthy Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="83852"></Trial><Drug id="10593">Meningitec</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>716</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>716</EnrollmentCount><Interventions>Meningitec; Priorix-Tetra</Interventions><Reference>115555; 115555MMRV-063; 2011-001608-37; MMRV-063; NCT01506193</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Clinical Trial to Assess the Safety of a Measles Vaccine (Dry Powder) Administered by Two Different Devices</ProtocolTitle><Sponsor>Serum Institute of India Ltd</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85837"></Trial><Drug id="57263">measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>60</Patients><Biomarkers>Anti-Measles antibodies; Immunoglobulin G; serum anti-Measles IgG</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>60</EnrollmentCount><Interventions>licensed subcutaneous measles vaccine; measles vaccine (inhaled dry powder/CAN-BD), Aktiv-Dry</Interventions><Reference>CTRI/2012/02/002447; NCT01557699; PMV-001</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94105"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>5016</Patients><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9859"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1000</Patients><Biomarkers>Meningococcal rSBA</Biomarkers><Condition>Measles virus infection</Condition><Controls>Meningitec; Priorix-Tetra</Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>Nimenrix; Nimenrix + Priorix-Tetra; Priorix-Tetra; Priorix-Tetra + Meningitec</Interventions><Reference>109670; NCT00474266</Reference></Row><Row><ArmCount>4+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A Study of Two Doses of Menactra, a Meningococcal Conjugate Vaccine in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9949"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1128</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><EnrollmentCount>1128</EnrollmentCount><Interventions>Menactra; Menactra; PCV; ROR Vax</Interventions><Reference>MTA44; NCT00384397</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and safety of GSK Biologicals malaria vaccine given at 6,7.5 and 9 months of age coadministered with measles,rubella and yellow fever vaccines</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="261663"></Trial><Drug id="14289">malaria vaccine, GlaxoSmithKline/Malaria Vaccine Initiative</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>700</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>MR-Vac; Stamaril; Vitamin A</Controls><EnrollmentCount>700</EnrollmentCount><Interventions>malaria vaccine, GlaxoSmithKline/Malaria Vaccine Initiative</Interventions><Reference>PACTR201602001483150</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to assess the safety and protective efficacy of Biological Es Measles-Rubella Vaccine in 9 to 12 months old Infants in India</ProtocolTitle><Sponsor>Biological E Ltd</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="266205"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>600</Patients><Biomarkers>Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Measles virus infection</Condition><Controls>SIIL’s MR-Vac</Controls><EnrollmentCount>600</EnrollmentCount><Interventions>measles/rubella vaccine, Biological E</Interventions><Reference>BECT036/MRV-PII/III/CTP-02; CTRI/2016/07/007109</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="307614"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>600</Patients><Biomarkers>Anti varicella zoster virus antibodies; Body temperature; Glycoproteins</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>600</EnrollmentCount><Interventions>M-M-R II; Varivax</Interventions><Reference>NCT03239873; V210-A03</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Clinical Trial for Measles - Rubella Combined Vaccine (MRVAC) Produced by POLYVAC (phase III)</ProtocolTitle><Sponsor>POLYVAC</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="357452"></Trial><Drug id="113162">MRVAC</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>756</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>MR vaccine (Serum Institute of India)</Controls><EnrollmentCount>756</EnrollmentCount><Interventions>MRVAC</Interventions><Reference>MRVAC VX.2016.01; NCT03713359</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Trial of Measles Virotherapy in Combination With Atezolizumab in Patients With Metastatic Non-Small Cell Lung Cancer</ProtocolTitle><Sponsor>Vyriad</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="273428"></Trial><Drug id="72699">atezolizumab</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>4</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>4</EnrollmentCount><Interventions>MV-NIS (lung cancer), Vyriad; atezolizumab</Interventions><Reference>NCT02919449; VYR-MV1-101</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Quadrivalent Meningococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Infants and Toddlers in the US</ProtocolTitle><Sponsor>Sanofi Pasteur</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="340960"></Trial><Drug id="39031">Menveo</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>2475</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-HBs antigen antibodies; Anti-Measles antibodies; Anti-Meningitis A antibodies; Anti-Meningitis C antibodies; Anti-Meningitis W antibodies; Anti-Meningitis W-135 antibodies; Anti-Meningitis Y antibodies; Anti-Parotitis virus antibodies; Anti-Rotavirus antibodies; Anti-Rubella antibodies; Anti-Streptococcus pneumoniae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>DTaP-IPV//Hib vaccine; Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Menveo; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine</Controls><EnrollmentCount>2475</EnrollmentCount><Interventions>Hepatitis A vaccine; Hepatitis B vaccine; Measles, mumps, rubella (MMR) vaccine; Pentaxim; Pneumococcal 13-valent conjugate vaccine; RotaTeq; Varicella vaccine; quadrivalent meningococcal tetanus toxoid conjugate vaccine (meningitis), Sanofi Pasteur</Interventions><Reference>MET42; NCT03537508</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10223"></Trial><Drug id="15298">Pentacel</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>216</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Reference>2006-003476-35; NCT00488683; V59P16</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MMR</ProtocolAcronym><ProtocolTitle>Comparative Study of the Immunogenicity of MMR (Measles, Mumps and Rubella) Single- Dose and Multidose Presentations</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="106360"></Trial><Drug id="94952">MMR vaccine, Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>240</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR (GSK-TV), GlaxoSmithKline</Controls><EnrollmentCount>240</EnrollmentCount><Interventions>MMR vaccine, Bio-Manguinhos/Fiocruz</Interventions><Reference>Asclin 003/2012; MMR; NCT01777529</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of a Combined Vaccine to Prevent Measles, Mumps, Rubella and Chickenpox Diseases</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11388"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>970</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>944</EnrollmentCount><Interventions>Priorix-Tetra</Interventions><Reference>104389; EudraCT: 2004-005263-19; NCT00127023</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Hepatitis A Vaccine, Inactivated and Measles, Mumps, Rubella and Varicella Virus Vaccine Live Safety Study</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11511"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1800</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1800</EnrollmentCount><Interventions>ProQuad; Vaqta</Interventions><Reference>2006_023; NCT00326183; V251-066</Reference></Row><Row><ArmCount>4</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Comparative Study of Immunogenicity and Safety of a two-dose Regimen of ProQuad Manufactured With rHA</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp, Sanofi Pasteur MSD</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11632"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1620</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1620</EnrollmentCount><Interventions>ProQuad; ProQuad (group 1); ProQuad (group 2); ProQuad (group 3)</Interventions><Reference>2007-002468-88; MRV02C; NCT00566527; V221-038</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Concomitant Administration of a New Hexavalent Vaccine With a Meningococcal Serogroup C Conjugate Vaccine in Healthy Infants During Primary Series Immunization Followed by Booster Vaccination</ProtocolTitle><Sponsor>Sanofi Pasteur MSD, Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="124248"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>312</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-Hepatitis B virus antibodies; Anti-Meningitis A virus antibodies; Anti-Meningitis C virus antibodies; Anti-Meningitis Y virus antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies; Anti-polyribitol phosphate antibodies; Anti-polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-RvaxPRO; Nimenrix; Prevnar 13; RotaTeq; V-419</Controls><EnrollmentCount>350</EnrollmentCount><Interventions>M-M-RvaxPRO; NeisVac-C; Nimenrix; Prevnar 13; RotaTeq; V-419</Interventions><Reference>2012-005547-24; EUCTR2012-005547-24; HXM01C; NCT01839175</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to evaluate frozen versus refrigerated MMRV (combined Measles, Mumps, Rubella, and Varicella) investigational vaccine</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="12456"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1200</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>1200</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2004_076; NCT00092430</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity, Safety of Measles-mumps-rubella-varicella Vaccine (MeMuRu-OKA) Compared to Priorix Given With Varilrix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="187831"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>400</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>400</EnrollmentCount><Interventions>Priorix-Tetra; Varilrix + Priorix</Interventions><Reference>105909; 2005-005825-75; NCT00352898</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Safety and Imunogenicity of Double Viral Vaccine (MR) for Measles and Rubella</ProtocolTitle><Sponsor>Bio-Manguinhos/Fiocruz</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="206205"></Trial><Drug id="99042">double viral vaccine (measles/rubella), Bio-Manguinhos/Fiocruz</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>30</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>30</EnrollmentCount><Interventions>double viral vaccine (measles/rubella), Bio-Manguinhos/Fiocruz</Interventions><Reference>ASCLIN 002/2014; NCT02196285</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233238"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym>MEMURU-OKA-049</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GSK Biologicals 208136 Vaccine Formulated With New Measles and Rubella Working Seeds</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="54026"></Trial><Drug id="17141">Priorix-Tetra</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>498</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix-Tetra</Controls><EnrollmentCount>501</EnrollmentCount><Interventions>208136 vaccine, new formulation</Interventions><Reference>108760; 2011-005881-38; MEMURU-OKA-049; MEMURU-OKA-049; NCT00892775</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60050"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>450</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>450</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Priorix-Tetra</Interventions><Reference>109995; 2011-005882-19; MMRV-053 PRI; NCT00969436</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>MMRV-053 PRI</ProtocolAcronym><ProtocolTitle>Comparison of GSK Measles-Mumps-Rubella-Varicella (MMRV) Vaccine Versus Priorix</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60050"></Trial><Drug id="9474">Varilrix</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>450</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix; Varilrix</Controls><EnrollmentCount>450</EnrollmentCount><Interventions>Priorix; Priorix-Tetra; Priorix-Tetra</Interventions><Reference>109995; 2011-005882-19; MMRV-053 PRI; NCT00969436</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60653"></Trial><Drug id="10530">Comvax</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>822</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Comvax; Tripedia; Varivax</Controls><EnrollmentCount>1913</EnrollmentCount><Interventions>Comvax; ProQuad; Tripedia</Interventions><Reference>2009_666; NCT00984295; V221-013</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77052"></Trial><Drug id="49241">Quadracel</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3340</Patients><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85664"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85664"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91153"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4538</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Phase II Study to Evaluate Safety and Immunogenicity of a Chikungunya Vaccine</ProtocolTitle><Sponsor>Themis Bioscience GmbH</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="268409"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>263</Patients><Biomarkers>Anti-Chikungunya virus antibodies; Anti-Measles antibodies; Mononuclear leukocytes; T-Lymphocytes</Biomarkers><Condition>Measles virus infection</Condition><Controls>Priorix</Controls><EnrollmentCount>263</EnrollmentCount><Interventions>MV-CHIK; MV-CHIK; Priorix</Interventions><Reference>2015-004037-26; MV-CHIK-202; NCT02861586</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A clinical trial to evaluate the safety and immunogenicity of HBI Measles and Rubella vaccine (Live) in two age groups of healthy male subjects</ProtocolTitle><Sponsor>Indian Immunologicals Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="377732"></Trial><Drug id="115970">live-attenuated viral vaccine (sc, measles/rubella virus infection), Indian Immunologicals</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>55</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>55</EnrollmentCount><Interventions>Measles and Rubella Vaccine (Live), HBI</Interventions><Reference>CTRI/2019/04/018635; HBI/MR/I/2018/001.01.00 Version 01</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Reactogenicity of a Trivalent MMR (Trivivac) in Healthy Infants</ProtocolTitle><Sponsor>Queen Sirikit National Institute of Child Health</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="104131"></Trial><Drug id="83793">Trivivac</Drug><DevStatus id="C23">Phase 2/Phase 3 Clinical</DevStatus><Patients>200</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Trivivac</Interventions><Reference>NCT01763268; Trivivac2012</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Concomitant Administration of MMR rHA and VARIVAX by Intramuscular Versus Subcutaneous Route</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11525"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>752</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><EnrollmentCount>752</EnrollmentCount><Interventions>Varivax</Interventions><Reference>EudraCT#2004_002586_21; NCT00432523; V205-011; X04-MMRr-301</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Sponsor>Health Protection Agency</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="132011"></Trial><Drug id="34281">Prevnar 13</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers>Immunoglobulin G; Serum bactericidal antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Menitorix; Prevnar 13; Priorix</Interventions><Reference>12/LO/1875; 2012-005110-18; HPA Protocol No: 12/05; ISRCTN84763401; P13Boost; UKCRN 13975</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase II, multicenter, open, randomized study to compare the safety and immunogenicity of MMR vaccine, Berna with MMR vaccine, Merck &amp; Co in children</ProtocolTitle><Sponsor>Crucell Switzerland AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="17279"></Trial><Drug id="41069">second-generation MMR vaccine, Berna</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>467</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>ROR Vax</Controls><EnrollmentCount>467</EnrollmentCount><Interventions>second-generation MMR vaccine, Berna</Interventions><Reference>PMID: 16371870</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study to Evaluate Safety, Dose Response and Immunogenicity of the Measles Vaccine MVA mBN85B in Healthy Children Aged 6 Months to 6 Years</ProtocolTitle><Sponsor>Bavarian Nordic A/S</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="59936"></Trial><Drug id="54328">MVA-mBN85B</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>90</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>90</EnrollmentCount><Interventions>MVA mBN85B</Interventions><Reference>MEA-HFN-002; NCT00891007</Reference></Row><Row><ArmCount>6</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Frozen ProQuad Administered Concomitantly Versus Nonconcomitantly With Other Pediatric Vaccines</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="60653"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>822</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Comvax; Tripedia; Varivax</Controls><EnrollmentCount>1913</EnrollmentCount><Interventions>Comvax; ProQuad; Tripedia</Interventions><Reference>2009_666; NCT00984295; V221-013</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of DTap-IPV Compared to Daptacel and IPOL as the Fifth Dose in Children 4 to 6 Years of Age</ProtocolTitle><Sponsor>Sanofi Pasteur Inc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="77052"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>3340</Patients><Biomarkers>Anti-poliovirus type 1 antibody; Anti-poliovirus type 2 antibody; Anti-poliovirus type 3 antibody; Body temperature; Diphtheria antibody; Filamentous hemagglutinin (FHA); Fimbriae type 2; Fimbriae type 3; Limb muscle; Pertactin (PRN); Pertussis toxoid (PT); Polio antibody; Tetanus antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls>Daptacel; Daptacel + IPOL + M-M-R II + Varivax; IPOL; M-M-R II; Varivax</Controls><EnrollmentCount>3372</EnrollmentCount><Interventions>M-M-R II; Quadracel; Quadracel + M-M-R II + Varivax; Varivax</Interventions><Reference>M5I02; NCT01346293; U1111-1116-4842</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79465"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1220</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference></Row><Row><ArmCount>3+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity of GSK's MMR Vaccine (209762) versus M-M-R II, When Given With Routine Vaccines at 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="79465"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>1220</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; M-M-R II + Varivax + Havrix + Prevnar; Prevnar; Varivax</Controls><EnrollmentCount>1259</EnrollmentCount><Interventions>Havrix; Prevnar; Priorix; Priorix (lot 2); Priorix (lot 3); Priorix + Varivax + Havrix + Prevnar; Varivax</Interventions><Reference>111870; 111870_; 2011-005860-31; 7229; MMR-157 PRI; NCT00861744</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of V-419 (PR-51) in Combination With MCC in Infants and Toddlers</ProtocolTitle><Sponsor>MCM Vaccine BV</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="85664"></Trial><Drug id="10774">NeisVac-C</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>284</Patients><Biomarkers>Polyribosylribitol phosphate</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>284</EnrollmentCount><Interventions>M-M-RvaxPRO; Men-C CRM liquid vaccine, Novartis; Menitorix; NeisVac-C; Prevnar 13; V-419</Interventions><Reference>2011-002413-11; NCT01553279; PRI01C; UKCRN ID: 11587; V419-011</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym>MMR-158</ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Combined Measles-mumps-rubella (MMR) Vaccine in Subjects 4 to 6 Years of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="88475"></Trial><Drug id="57017">Kinrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4011</Patients><Biomarkers>Anti-Bordetella pertussis antibodies; Anti-Bordetella pertussis filamentous hemagglutinin adhesin antibodies; Anti-Bordetella pertussis pertactin antibodies; Anti-Clostridium tetani antibodies; Anti-Corynebacterium diphtheriae antibodies; Anti-poliovirus type 1 antibodies; Anti-poliovirus type 2 antibodies; Anti-poliovirus type 3 antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls>Infanrix-IPV; MMR vaccine, Merck &amp; Co; ProQuad</Controls><EnrollmentCount>4011</EnrollmentCount><Interventions>Infanrix-IPV; MMR vaccine, Merck &amp; Co; Priorix; Priorix; ProQuad</Interventions><Reference>115158; 2011-004638-32; 209762; MMR-158; NCT01621802</Reference></Row><Row><ArmCount>5</ArmCount><ProtocolAcronym>MMR-160</ProtocolAcronym><ProtocolTitle>Consistency Study of GlaxoSmithKline(GSK) Biologicals MMR Vaccine (209762)(Priorix) Comparing Immunogenicity and Safety to Merck and Co Inc's MMR Vaccine (MMR II) in Children 12 to 15 Months of Age</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="94105"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>5016</Patients><Biomarkers>Anti varicella zoster virus antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR vaccine, Merck &amp; Co</Controls><EnrollmentCount>5016</EnrollmentCount><Interventions>Priorix</Interventions><Reference>115648; 2011-004891-12; MMR-160; NCT01702428</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A phase-I study to evaluate the safety and tolerability of Measles Rubella(MR) vaccine in 4 to 5 years old healthy children in a single-dose schedule</ProtocolTitle><Sponsor>Biological E Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="246741"></Trial><Drug id="95202">MRBEV</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>measles/rubella vaccine, Biological E</Interventions><Reference>BECT032/MRV-PI/CTP-02; CTRI/2015/11/006375</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>BMR-3</ProtocolAcronym><ProtocolTitle>Third MMR Vaccine Dose In Young Adults</ProtocolTitle><Sponsor>National Institute for Public Health and the Environment</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="270107"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>150</Patients><Biomarkers>Anti-Parotitis virus antibodies; B-lymphocytes; Immunoglobulin A; Immunoglobulin G; Memory B-Lymphocytes; Memory T-Lymphocytes; T-Lymphocytes</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>150</EnrollmentCount><Interventions>M-M-RvaxPRO</Interventions><Reference>BMR-3; NL57282.094.16 IIV-291; NTR5911</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety and Efficacy of ProQuad in Children 6 to 24 Months Being Evaluated for Solid Organ Transplant</ProtocolTitle><Sponsor>Medical University of South Carolina</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="254035"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C12">Phase 1/Phase 2 Clinical</DevStatus><Patients>5</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>5</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>NCT02687763; PRO25854</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of Immunogenicity and Safety of VARIVAX Passage Extension 34 (PE34) Process in Children</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="307614"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>600</Patients><Biomarkers>Anti varicella zoster virus antibodies; Body temperature; Glycoproteins</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>600</EnrollmentCount><Interventions>M-M-R II; Varivax</Interventions><Reference>NCT03239873; V210-A03</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>MMR at 6 Months Trial</ProtocolTitle><Sponsor>Danish National University Hospital, Rigshospitalet, Denmark</Sponsor><TrialStatus>Recruiting</TrialStatus><Trial id="364134"></Trial><Drug id="89684">M-M-RvaxPRO</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>6500</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Hydrocortisone; Immunoglobulin G; Immunoglobulin G/Immunoglobulin M ratio; Interleukin-1 beta; Interleukin-6; Pancreatic alpha-amylase; Tumor necrosis factor</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>6500</EnrollmentCount><Interventions>M-M-RvaxPRO</Interventions><Reference>2016-001901-18; LGS.MMR.01.2016.2022; NCT03780179</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>B Cell Response to a Primary and a Booster Course of the Novartis Meningococcal ACWY Conjugate Vaccine in Healthy Infants</ProtocolTitle><Sponsor>Novartis AG</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10223"></Trial><Drug id="39031">Menveo</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>216</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>216</EnrollmentCount><Interventions>MenACWY-CRM; Pediacel; Prevnar; Priorix; Vaxem HIB</Interventions><Reference>2006-003476-35; NCT00488683; V59P16</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10810"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>300</Patients><Biomarkers>CD4</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>Pneumovax 23; Prevnar</Interventions><Reference>10609; ACTG P1024; NCT00013871; P1024; PACTG 1024</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Pneumococcal Vaccine and Routine Pediatric Immunizations in HIV-Infected Children Receiving Anti-HIV Drugs</ProtocolTitle><Sponsor>National Institute of Allergy and Infectious Diseases</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="10810"></Trial><Drug id="7080">Pneumovax 23</Drug><DevStatus id="NS">Phase not specified</DevStatus><Patients>300</Patients><Biomarkers>CD4</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>300</EnrollmentCount><Interventions>Pneumovax 23; Prevnar</Interventions><Reference>10609; ACTG P1024; NCT00013871; P1024; PACTG 1024</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety Study of a Refrigerator-Stable Formulation of Varivax</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="11524"></Trial><Drug id="4645">varicella-zoster vaccine (Varivax/Zostavax)</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>507</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>M-M-R II</Controls><EnrollmentCount>500</EnrollmentCount><Interventions>Varivax</Interventions><Reference>2004-002669-19; NCT00432731; V210-061; X04-VAR-402</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym>P13Boost</ProtocolAcronym><ProtocolTitle>Responses to booster vaccinations in UK toddlers</ProtocolTitle><Sponsor>Health Protection Agency</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="132011"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>200</Patients><Biomarkers>Immunoglobulin G; Serum bactericidal antibody</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>200</EnrollmentCount><Interventions>Menitorix; Prevnar 13; Priorix</Interventions><Reference>12/LO/1875; 2012-005110-18; HPA Protocol No: 12/05; ISRCTN84763401; P13Boost; UKCRN 13975</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety, Tolerability, and Immunogenicity of Measles, Mumps, Rubella, and Varicella (MMRV) Vaccine Made With an Alternative Manufacturing Process (AMP)</ProtocolTitle><Sponsor>Merck Sharp &amp; Dohme Corp</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="184151"></Trial><Drug id="3643">M-M-R II</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1412</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls>ProQuad</Controls><EnrollmentCount>1412</EnrollmentCount><Interventions>M-M-R II</Interventions><Reference>2017-001443-13; NCT01536405; P20930; V221-027</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym>BREMEAVAC</ProtocolAcronym><ProtocolTitle>Search for the Measles Vaccine Virus Excretion in Breast Milk of Breastfeeding Women After Postpartum Vaccination With MMR</ProtocolTitle><Sponsor>Assistance Publique Hopitaux de Paris, Centre Hospitalier Universitaire de Limoges</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="218981"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>14</Patients><Biomarkers>Immunoglobulin G; Immunoglobulin M</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>14</EnrollmentCount><Interventions>Priorix</Interventions><Reference>2014-001538-28; BREMEAVAC; NCT02325310; P130930</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233238"></Trial><Drug id="11458">Menitorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym>Sched3</ProtocolAcronym><ProtocolTitle>Baby Vaccine Study</ProtocolTitle><Sponsor>Bill &amp; Melinda Gates Foundation, National Institute for Health Research (NIHR), University of Oxford</Sponsor><TrialStatus>No longer recruiting</TrialStatus><Trial id="233238"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C2">Phase 2 Clinical</DevStatus><Patients>213</Patients><Biomarkers>Anti-Clostridium tetani antibodies; Anti-polyribitol phosphate antibodies; Body temperature; Immunoglobulin G</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>189</EnrollmentCount><Interventions>Bexsero; Infanrix-DTaP-IPV-Hib; Menitorix; Prevnar 13; Priorix; Rotarix</Interventions><Reference>2015-000817-32; NCT02482636; OVG2015/03; Sched3</Reference></Row><Row><ArmCount>2</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>A study of ProQuad in healthy Korean children</ProtocolTitle><Sponsor>Merck &amp; Co Inc</Sponsor><TrialStatus>Terminated</TrialStatus><Trial id="44865"></Trial><Drug id="47279">ProQuad</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>30</Patients><Biomarkers>Anti varicella zoster virus antibodies; Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>MMR II; Varivax</Controls><EnrollmentCount>30</EnrollmentCount><Interventions>ProQuad</Interventions><Reference>2009_538; NCT00839917; V221-023</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91153"></Trial><Drug id="11457">Priorix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4538</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference></Row><Row><ArmCount>1+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biological's Combined Measles-mumps-rubella (MMR) Vaccine in Children in Their Second Year of Life</ProtocolTitle><Sponsor>GlaxoSmithKline Biologicals, GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="91153"></Trial><Drug id="6621">Havrix</Drug><DevStatus id="C3A">Phase 3a Clinical</DevStatus><Patients>4538</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies; Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>Havrix; M-M-R II; Prevnar 13; Varivax</Controls><EnrollmentCount>4538</EnrollmentCount><Interventions>Havrix; Prevnar 13; Priorix; Varivax</Interventions><Reference>115649; 15049; 2011-004905-26; MMR-161; NCT01681992; NMRR-13-165-15049</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Safety And Immunogenicity Study of Meningococcal Vaccine GSK-134612 Given With Priorix-Tetra to 12 to 23 Months-Old Children</ProtocolTitle><Sponsor>GlaxoSmithKline plc</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9859"></Trial><Drug id="10593">Meningitec</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1000</Patients><Biomarkers>Meningococcal rSBA</Biomarkers><Condition>Measles virus infection</Condition><Controls>Meningitec; Priorix-Tetra</Controls><EnrollmentCount>1000</EnrollmentCount><Interventions>Nimenrix; Nimenrix + Priorix-Tetra; Priorix-Tetra; Priorix-Tetra + Meningitec</Interventions><Reference>109670; NCT00474266</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9965"></Trial><Drug id="4144">Prevnar</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1378</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>HepA; MMRV; Prevnar</Controls><EnrollmentCount>1378</EnrollmentCount><Interventions>HepA; Menactra; Menactra; Prevnar; ProQuad</Interventions><Reference>MTA48; NCT00483574</Reference></Row><Row><ArmCount>2+</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study of the Safety of Menactra Vaccine When Administered With Other Pediatric Vaccines to Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9965"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1378</Patients><Biomarkers>Body temperature</Biomarkers><Condition>Measles virus infection</Condition><Controls>HepA; MMRV; Prevnar</Controls><EnrollmentCount>1378</EnrollmentCount><Interventions>HepA; Menactra; Menactra; Prevnar; ProQuad</Interventions><Reference>MTA48; NCT00483574</Reference></Row><Row><ArmCount>3</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Immunogenicity and Safety of Pediatric Vaccines When Administered With Menactra in Healthy Toddlers</ProtocolTitle><Sponsor>Sanofi SA</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="9967"></Trial><Drug id="30177">Menactra</Drug><DevStatus id="C3">Phase 3 Clinical</DevStatus><Patients>1664</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls>Haemophilus influenzae B (Hib) vaccine, Aventis Pasteur; ROR Vax</Controls><EnrollmentCount>1664</EnrollmentCount><Interventions>Menactra</Interventions><Reference>MTA37; NCT00422292</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>To Assess the Safety and Tolerability of Measles, Mumps, Rubella and Varicella Vaccine (Live-Attenuated, Freeze-Dried) in Healthy Adult Male Human Subjects</ProtocolTitle><Sponsor>Zydus Cadila Healthcare Ltd</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="243853"></Trial><Drug id="97994">MMRV vaccine, Zydus Cadila Healthcare</Drug><DevStatus id="C1">Phase 1 Clinical</DevStatus><Patients>24</Patients><Biomarkers>Blood pressure; Body temperature; Heart rate; Respiratory frequency</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>24</EnrollmentCount><Interventions>MMRV vaccine, Zydus Cadila Healthcare</Interventions><Reference>CTRI/2015/10/006291; MMRVC 1001</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Evaluation of the immunogenicity and safety of Japanese encephalitis vaccine when given with measles-mumps-rubella vaccine</ProtocolTitle><Sponsor>Path Inc, Syneos Health Inc</Sponsor><TrialStatus>Not yet recruiting</TrialStatus><Trial id="268796"></Trial><Drug id="60890">SA-14-14-2</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>628</Patients><Biomarkers></Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>628</EnrollmentCount><Interventions>SA-14-14-2</Interventions><Reference>2016-CT0360; JEV06; PHRR160822-001339</Reference></Row><Row><ArmCount>1</ArmCount><ProtocolAcronym></ProtocolAcronym><ProtocolTitle>Study on Immunization Schedule of Beijing Tiantan Biological's Measles-mumps-rubella(MMR) Vaccine</ProtocolTitle><Sponsor>The Chinese Centre for Disease Control and Prevention</Sponsor><TrialStatus>Completed</TrialStatus><Trial id="298801"></Trial><Drug id="79144">measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Drug><DevStatus id="C4">Phase 4 Clinical</DevStatus><Patients>873</Patients><Biomarkers>Anti-Measles antibodies; Anti-Parotitis virus antibodies; Anti-Rubella antibodies</Biomarkers><Condition>Measles virus infection</Condition><Controls></Controls><EnrollmentCount>873</EnrollmentCount><Interventions>measles/mumps/rubella vaccine (live-attenuated),  Beijing Tiantan Biological Products</Interventions><Reference>BJCDCWJ201601; NCT03160820</Reference></Row></ns2:com.thomsonreuters.ls.service.contract.analytics.v2.soap.AnalyticsOutputV2>